Enrollment complete in Unigene's oral PTH Phase 2 osteoporosis study in postmenopausa

[News]

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company has completed patient enrollment of its Phase 2 study with an experimental oral parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

More... (http://www.news-medical.net/news/20110428/Enrollment-complete-in-Unigenes-oral-PTH-Phase-2-osteoporosis-study-in-postmenopausal-women.aspx)